Related references
Note: Only part of the references are listed.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Karen L. Bride et al.
BLOOD (2018)
An off-the-shelf fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Matthew L. Cooper et al.
LEUKEMIA (2018)
COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.
Kimberly P. Dunsmore et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization
Stuart S. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
Marion Alcantara et al.
LEUKEMIA (2018)
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma
Yasmin Abaza et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Yana Pikman et al.
CLINICAL CANCER RESEARCH (2017)
PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature
Evgeni Efimenko et al.
MOLECULAR CANCER THERAPEUTICS (2017)
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Yu Liu et al.
NATURE GENETICS (2017)
Synergistic antileukemic therapies in NOTCH1-induced T-ALL
Marta Sanchez-Martin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies
Yi Tian Png et al.
BLOOD ADVANCES (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
Management of adults with T-cell lymphoblastic leukemia
David I. Marks et al.
BLOOD (2017)
The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia
Marta Sanchez-Martin et al.
BLOOD (2017)
Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma
Marlise R. Luskin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia
N. Jena et al.
LEUKEMIA (2016)
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Moericke et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias
Nirali N. Shah et al.
PEDIATRIC BLOOD & CANCER (2016)
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study
A. Desjonqueres et al.
BLOOD CANCER JOURNAL (2016)
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Laura Belver et al.
NATURE REVIEWS CANCER (2016)
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Maksim Mamonkin et al.
BLOOD (2015)
CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia
Diana Passaro et al.
CANCER CELL (2015)
The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia
Nancy Pinnell et al.
IMMUNITY (2015)
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
Ashvinikumar V. Gavai et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
Cristina Papayannidis et al.
BLOOD CANCER JOURNAL (2015)
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia
D. J. DeAngelo et al.
LEUKEMIA (2015)
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells
Justine E. Roderick et al.
BLOOD (2014)
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Sofie Peirs et al.
BLOOD (2014)
Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
Katharine Patrick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts
V. Agnusdei et al.
LEUKEMIA (2014)
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
P. Jain et al.
LEUKEMIA (2014)
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis
Wenli Zheng et al.
LEUKEMIA & LYMPHOMA (2014)
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Birgit Knoechel et al.
NATURE GENETICS (2014)
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Triona Ni Chonghaile et al.
CANCER DISCOVERY (2014)
Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer
Giovanni Roti et al.
CANCER CELL (2013)
Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia
Erich Piovan et al.
CANCER CELL (2013)
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
Jeffrey A. Silverman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
Graca M. Dores et al.
BLOOD (2012)
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Catherine M. Sawai et al.
CANCER CELL (2012)
Targeting Nonclassical Oncogenes for Therapy in T-ALL
Prem S. Subramaniam et al.
CANCER CELL (2012)
Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Kimberly P. Dunsmore et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Jeremy B. Samon et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang et al.
NATURE (2012)
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2011)
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe et al.
BLOOD (2011)
Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)
Barbara L. Asselin et al.
BLOOD (2011)
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia
Maddalena Paganin et al.
BLOOD REVIEWS (2011)
NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse
Sarah Clarke et al.
LEUKEMIA RESEARCH (2011)
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma
Leah A. Commander et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Therapeutic antibody targeting of individual Notch receptors
Yan Wu et al.
NATURE (2010)
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Alejandro Gutierrez et al.
BLOOD (2009)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
David I. Marks et al.
BLOOD (2009)
Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria - A population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group
Bettina Reismueller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Elaine Coustan-Smith et al.
LANCET ONCOLOGY (2009)
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia
W. Deenik et al.
LEUKEMIA (2009)
Direct inhibition of the NOTCH transcription factor complex
Raymond E. Moellering et al.
NATURE (2009)
gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia
Pedro J. Real et al.
NATURE MEDICINE (2009)
The role of the PTEN/AKT pathway in NOTCH1-induced leukemia
Teresa Palomero et al.
CELL CYCLE (2008)
In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia
Kim De Keersmaecker et al.
HAEMATOLOGICA (2008)
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies
A. Quintas-Cardama et al.
LEUKEMIA (2008)
FDA drug approval summary: Nelarabine (Arranon (R)) for the treatment of T-cell lymphoblastic leukemia/lymphoma
Martin H. Cohen et al.
ONCOLOGIST (2008)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero et al.
NATURE MEDICINE (2007)
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors
Jennifer O'Neil et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Daniel J. DeAngelo et al.
BLOOD (2007)
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
Meir Wetzler et al.
BLOOD (2007)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
NUP214-ABL1 in adult T-ALL:: the GMALL study group experience
Thomas Burmeister et al.
BLOOD (2006)
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
Guo Wei et al.
CANCER CELL (2006)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-Cell malignancies: A report from the children's oncology group
SL Berg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies
J Kurtzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia
C Graux et al.
NATURE GENETICS (2004)
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia
AP Weng et al.
SCIENCE (2004)
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies
DF Kisor et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)